Lansoprazole SUN Pharma

What Is Lansoprazole SUN Pharma and What Is It Used For?

Lansoprazole belongs to the class of medications known as proton pump inhibitors (PPIs), which are among the most widely prescribed drugs worldwide. The active substance, lansoprazole, is a substituted benzimidazole that selectively and irreversibly inhibits the hydrogen-potassium adenosine triphosphatase (H+/K+-ATPase) enzyme system—commonly referred to as the gastric proton pump—at the secretory surface of gastric parietal cells. This enzyme is responsible for the final step in the production of hydrochloric acid in the stomach.

By blocking this proton pump, lansoprazole effectively reduces both basal and stimulated gastric acid secretion regardless of the stimulus. The onset of acid suppression typically occurs within one to three hours after oral administration, and the antisecretory effect persists for more than 24 hours due to the irreversible nature of enzyme inhibition. Full therapeutic effect is usually achieved within two to three days of regular dosing, as more proton pumps are progressively inhibited with each subsequent dose.

Lansoprazole SUN Pharma is specifically formulated as an orodispersible tablet. This means the tablet is designed to be placed on the tongue, where it rapidly disintegrates and disperses with saliva. The resulting suspension of enteric-coated microgranules is then swallowed. This formulation is particularly advantageous for patients who experience difficulty swallowing (dysphagia), elderly patients, pediatric patients, and those who may not have access to water at the time of dosing.

Approved Indications

Lansoprazole SUN Pharma 15 mg is indicated for a range of acid-related gastrointestinal disorders. The specific indications and dosing may vary slightly depending on regulatory authority and country, but the following represent the core therapeutic uses recognized internationally:

• Gastroesophageal Reflux Disease (GERD): Treatment and maintenance of erosive and non-erosive reflux disease, including symptomatic relief of heartburn and acid regurgitation.
• Duodenal Ulcer: Short-term treatment of active duodenal ulcer and maintenance therapy to prevent relapse.
• Gastric Ulcer: Treatment of benign active gastric ulcer, including NSAID-associated gastric ulcers.
• Erosive Esophagitis: Healing and maintenance of healed erosive esophagitis.
• Helicobacter pylori Eradication: As part of combination regimens (typically triple therapy with two antibiotics) for the eradication of H. pylori to reduce the risk of ulcer recurrence.
• Zollinger-Ellison Syndrome: Long-term management of pathological hypersecretory conditions.
• NSAID-Associated Ulcer Prophylaxis: Prevention of gastric and duodenal ulcers in patients requiring chronic NSAID therapy.

The 15 mg strength is most commonly used for maintenance therapy and milder indications, while higher doses (typically 30 mg) may be required for active disease treatment. Your prescribing physician will determine the appropriate dose and duration based on your specific condition and medical history.

What Should You Know Before Taking Lansoprazole SUN Pharma?

Before starting treatment with Lansoprazole SUN Pharma, it is essential that your healthcare provider has a complete picture of your medical history, current medications, and any allergies. PPIs are generally well tolerated, but certain conditions and drug interactions require careful consideration and, in some cases, may preclude the use of this medication.

Contraindications

Lansoprazole is contraindicated in patients with known hypersensitivity to lansoprazole, to any other substituted benzimidazole (including omeprazole, esomeprazole, pantoprazole, and rabeprazole), or to any of the excipients of the formulation. Cross-sensitivity between different PPIs has been documented in clinical literature, so patients who have experienced allergic reactions to one PPI should exercise caution with any other PPI.

Lansoprazole must not be taken concurrently with atazanavir or nelfinavir. The acid-suppressive effect of lansoprazole substantially reduces plasma concentrations of these HIV protease inhibitors, which may lead to loss of therapeutic effect and development of HIV resistance. This is a pharmacokinetic interaction that cannot be overcome by dose adjustment, and alternative acid-suppressive therapy should be considered for patients taking these antiretroviral agents.

Warnings and Precautions

Several important warnings apply to the use of lansoprazole. First, PPI therapy may mask the symptoms of gastric malignancy. Therefore, before initiating treatment, the possibility of gastric cancer should be excluded, particularly in patients presenting with new or recently changed dyspeptic symptoms, unintentional weight loss, recurrent vomiting, dysphagia, or hematemesis. An upper gastrointestinal endoscopy may be warranted in these cases.

Long-term PPI therapy, especially when used for more than one year and at high doses, has been associated with a modestly increased risk of hip, wrist, and spine fractures, particularly in elderly patients or those with other risk factors for osteoporosis. The European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) have both issued guidance recommending that patients on long-term PPI therapy should receive adequate vitamin D and calcium supplementation, and that the lowest effective dose should be used for the shortest necessary duration.

Hypomagnesemia (low blood magnesium levels) has been reported in patients taking PPIs for extended periods (typically more than three months, though most cases occur after one year of therapy). Symptoms of hypomagnesemia may include fatigue, muscle cramps, tremors, seizures, and cardiac arrhythmias. Healthcare providers should consider monitoring magnesium levels periodically in patients expected to be on prolonged PPI therapy, and particularly in those taking other medications known to cause hypomagnesemia (e.g., diuretics, digoxin).

PPI use has been associated with an increased risk of Clostridioides difficile (C. difficile) infection, particularly in hospitalized patients. Reduced gastric acidity may allow colonization by C. difficile. Patients who develop persistent diarrhea during PPI therapy should be evaluated for C. difficile infection.

Pregnancy and Breastfeeding

Lansoprazole is classified as FDA Pregnancy Category B, meaning that animal reproduction studies have not demonstrated a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Clinical experience with lansoprazole during pregnancy is limited, and the drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. If acid suppression is required during pregnancy, your doctor may consider alternatives with more extensive safety data.

Lansoprazole is excreted in animal milk, but it is not known whether it is excreted in human breast milk. Because many drugs are excreted in human milk and because of the potential for adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother. Discuss the risks and benefits with your healthcare provider before using lansoprazole while breastfeeding.

Liver and Kidney Disease

Lansoprazole is extensively metabolized by the liver. Patients with severe hepatic impairment may require dose adjustment, as the clearance of the drug is significantly reduced in these individuals, leading to increased exposure. A maximum dose of 15 mg daily is generally recommended in patients with severe liver disease. Regular monitoring of liver function may be appropriate during treatment.

No dose adjustment is generally required for patients with renal impairment, as lansoprazole is primarily metabolized hepatically. However, patients with end-stage renal disease should be monitored, as limited data are available in this population.

How Does Lansoprazole SUN Pharma Interact with Other Drugs?

Drug interactions with lansoprazole can occur through several mechanisms. As a potent acid suppressant, it alters gastrointestinal pH, which can affect the absorption of drugs that depend on an acidic environment for dissolution or stability. Additionally, lansoprazole is metabolized primarily by cytochrome P450 enzymes CYP2C19 and CYP3A4, creating the potential for pharmacokinetic interactions with other drugs metabolized by or inhibiting these enzymes.

Understanding these interactions is crucial for safe and effective therapy. The following table summarizes the most clinically significant drug interactions with lansoprazole. Always provide your healthcare provider with a complete list of all medications, over-the-counter products, vitamins, and herbal supplements you are taking before starting lansoprazole.

Major Interactions

Minor Interactions

What Is the Correct Dosage of Lansoprazole SUN Pharma?

The dosage of Lansoprazole SUN Pharma depends on the specific condition being treated, its severity, and individual patient factors such as age, weight, hepatic function, and response to treatment. The following dosage recommendations are based on international clinical guidelines and product labeling. Always follow the dosage prescribed by your healthcare provider, as it may differ from the general recommendations below.

Adults

Children

The use of lansoprazole in children is generally limited and varies by country. In the United States, lansoprazole is approved for children aged 1–17 years for GERD and erosive esophagitis. The recommended doses are:

• Children weighing ≤30 kg: 15 mg once daily for up to 12 weeks.
• Children weighing >30 kg: 30 mg once daily for up to 12 weeks.

In the European Union, the approved indications for children may differ, and the medication is often used off-label in pediatric populations. Treatment in children should always be supervised by a pediatric gastroenterologist or a physician experienced in pediatric gastroenterology. The orodispersible tablet formulation can be particularly useful for younger children who cannot swallow capsules.

Elderly

No specific dose adjustment is generally required in elderly patients based solely on age. However, elderly patients may be more susceptible to the long-term risks associated with PPI therapy, including bone fractures, hypomagnesemia, and vitamin B12 deficiency. The lowest effective dose should be used for the shortest necessary duration. If hepatic function is impaired, dose reduction should be considered as described above.

Missed Dose

If you miss a dose of lansoprazole, take it as soon as you remember, provided it is not close to the time of your next scheduled dose. If it is nearly time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you frequently forget doses, consider setting a daily reminder or using a pill organizer to help maintain consistency.

Overdose

How to Take the Orodispersible Tablet

1. Remove the tablet from the blister pack with dry hands. Do not push the tablet through the foil.
2. Place the tablet on your tongue. It will disintegrate rapidly with saliva.
3. Swallow the dispersed microgranules with or without a sip of water.
4. Do not chew, break, or crush the tablet, as the enteric-coated granules are designed to protect the active ingredient from stomach acid.
5. Take the tablet at least 30 minutes before a meal, preferably at the same time each day (usually in the morning).

For patients with nasogastric tubes, the orodispersible tablet can be dispersed in a small amount of water (approximately 10 mL) and administered through the tube. Ensure the tube is flushed with additional water to deliver the full dose.

What Are the Side Effects of Lansoprazole SUN Pharma?

Like all medicines, Lansoprazole SUN Pharma can cause side effects, although not everybody gets them. Most side effects associated with lansoprazole are mild to moderate in severity and resolve upon discontinuation or dose reduction. The frequency of side effects is classified according to international convention using the following categories:

Long-Term Safety Considerations

When lansoprazole is used for prolonged periods, several additional safety concerns have been identified through post-marketing surveillance and epidemiological studies. While the absolute risks remain low, patients and prescribers should be aware of these potential complications:

• Bone fractures: Observational studies have shown a modestly increased risk of hip, wrist, and vertebral fractures with long-term PPI use, particularly in elderly patients and those with additional risk factors for osteoporosis. The risk appears to increase with higher doses and longer duration of therapy.
• Vitamin B12 deficiency: Chronic acid suppression can reduce the absorption of dietary vitamin B12 (cyanocobalamin), which requires an acidic environment for release from food proteins. Deficiency may develop after one or more years of continuous PPI use and can manifest as anemia, neuropathy, or cognitive changes.
• Magnesium deficiency: Symptomatic and asymptomatic hypomagnesemia has been reported. This is of particular concern in patients also taking diuretics or other medications that can lower magnesium levels.
• Clostridioides difficile infection: By reducing the gastric acid barrier, PPIs may increase susceptibility to enteric infections, particularly C. difficile. This risk is most significant in hospitalized patients and those receiving concurrent antibiotic therapy.
• Fundic gland polyps: Benign polyps of the gastric fundus may develop with long-term PPI use. These are generally non-neoplastic and typically regress after discontinuation.

How Should You Store Lansoprazole SUN Pharma?

Proper storage of Lansoprazole SUN Pharma is important to maintain the quality, safety, and efficacy of the medication. The orodispersible tablet formulation is particularly sensitive to moisture, as the tablet is designed to disintegrate rapidly upon contact with liquid. Improper storage could result in premature tablet disintegration or degradation of the active ingredient.

• Temperature: Store below 25°C (77°F). Do not freeze. Avoid exposure to excessive heat or direct sunlight.
• Moisture protection: Keep the tablets in their original blister packaging until immediately before use. Do not transfer to pill organizers or other containers unless they provide adequate moisture protection.
• Light protection: Store in the original carton to protect from light.
• Handling: Handle the tablets with dry hands to prevent premature disintegration.
• Children: Keep out of the sight and reach of children.
• Expiry date: Do not use after the expiry date stated on the blister and carton. The expiry date refers to the last day of that month.

Do not dispose of unused or expired medications by flushing them down the toilet or pouring them into drains. Return any unused medication to your pharmacist for safe disposal in accordance with local regulations. This helps to protect the environment and prevents accidental exposure.

What Does Lansoprazole SUN Pharma Contain?

Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific ingredients. The complete composition of Lansoprazole SUN Pharma 15 mg orodispersible tablets is detailed below.

Active Ingredient

Each orodispersible tablet contains 15 mg of lansoprazole. Lansoprazole (chemical name: 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole) is a substituted benzimidazole with a molecular weight of 369.36 g/mol. It is a racemic mixture that is practically insoluble in water and degrades rapidly in acidic conditions, which is why the granules within the tablet are enteric-coated.

Excipients (Inactive Ingredients)

The orodispersible tablet formulation contains several inactive ingredients that serve various pharmaceutical functions:

• Mannitol: Used as a tablet filler and sweetener to improve palatability of the orodispersible formulation.
• Methacrylic acid copolymer (Type C): Forms the enteric coating on the lansoprazole microgranules, protecting them from degradation in the acidic stomach environment.
• Magnesium carbonate: Acts as a pH-adjusting agent and stabilizer.
• Sodium lauryl sulfate: Functions as a wetting agent to improve drug dissolution.
• Sugar spheres (sucrose and starch): Serve as the core upon which the drug layer and enteric coating are applied.
• Talc: Used as a glidant to prevent granules from sticking together.
• Polyethylene glycol (macrogol): Acts as a plasticizer in the enteric coating.
• Titanium dioxide (E171): Used as a coating colorant and opacifier.
• Polysorbate 80: Acts as a surfactant to improve dispersion.
• Strawberry flavoring: Added to improve the taste of the orodispersible formulation.
• Aspartame (E951): Artificial sweetener. Note: Contains a source of phenylalanine, which may be harmful for people with phenylketonuria (PKU). Each 15 mg tablet contains approximately 2.5 mg of aspartame, equivalent to 1.4 mg of phenylalanine.

Physical Description

Lansoprazole SUN Pharma 15 mg orodispersible tablets are round or oval, flat tablets with a white to off-white color and strawberry flavor. The tablet may contain visible speckled granules. When placed on the tongue, the tablet matrix disintegrates within approximately 30 seconds, leaving the enteric-coated lansoprazole microgranules dispersed in saliva for swallowing.

References

1. European Medicines Agency (EMA). Lansoprazole – Summary of Product Characteristics. EMA/CHMP. Available from: www.ema.europa.eu.
2. U.S. Food and Drug Administration (FDA). Prevacid (lansoprazole) – Prescribing Information. FDA Reference ID. Available from: FDA Drug Label.
3. World Health Organization. WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization; 2023.
4. Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017;11(1):27–37. doi:10.5009/gnl15502.
5. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–715. doi:10.1053/j.gastro.2017.01.031.
6. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019;157(3):682–691.e2. doi:10.1053/j.gastro.2019.05.056.
7. National Institute for Health and Care Excellence (NICE). Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. Clinical guideline [CG184]. 2014 (updated 2019).
8. Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27–56. doi:10.14309/ajg.0000000000001538.
9. British National Formulary (BNF). Lansoprazole. NICE Evidence Services. Available from: bnf.nice.org.uk.
10. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index – A02BC03 Lansoprazole. Available from: www.whocc.no.

Editorial Team